The United States of America As Represented by the Department of Health

The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of Minnesota

Amgen Inc.

Other

The United States of America As Represented by the Secretary of Health

Sharon M Wahl

Leo T Furcht

James B McCarthy

Janice B Allen

Stephen P Eisenberg

Robert C Thompson

Teresa Greenwell-Wild

Nancy L McCartney-Francis

Jeffrey E Everett

Kevin L Billups

Nancy Vazquez-Maldonado

David J Dripps

This invention relates to methods and compositions for the attenuation of HIV-1 replication in human cells, and especially in human macrophages. The invention particularly concerns the use of inhibitors of P21 (CDKNIA) expression to attenuate such replication. The invention particularly concerns the use of antisense P21 oligonucleotides, siRNA and/or 2-cyano-3,12-dioxooleana-1,9-dien28-oic (CDDO) to attenuate such replication.

Methods and compositions for the inhibition of HIV-1 replication

Methods and pharmaceutical compositions are provided to prevent retroviral infections of host cells. More particularly, the invention relates to prevention of HIV infection of human cells by serine leukocyte protease inhibitor (SLPI).

Inhibition of retrovirus infection

Methods for treating ischemia using polypeptides with fibronectin related activity are provided. The methods involve administering an effective amount of one or more polypeptides which include an amino acid sequence corresponding substantially to isolated an amino acid sequence from the 33 kD carboxy terminal heparin-binding region located on the A chain of fibronectin or an RGD-containing amino acid sequence within the 11.5 kD RGDS-mediated cell adhesion region located on all isoforms of fibronectin.

Method for treating ischemia using polypeptides with fibronectin activity

A method for treating acute or chronic inflammatory or autoimmune disorders using polypeptides with fibronectin or related activity is provided. The method involves (administering an amount of) one or more polypeptides corresponding to isolated amino acid residue sequences of the 33 kD carboxy terminal heparin-binding region located on the A chain of fibronectin to effectively suppress inflammation and impairment of tissue function in a patient.

Method for treating acute and chronic inflammatory disorders using

The invention includes methods for inhibiting retroviral infections such as HIV. The methods of this invention involve the use of certain fragments of fibronectin and such fragments conjugated to carrier molecules such as ovalbumin to inhibit retroviral infections. The invention also includes novel proteins which comprise fibronectin fragments covalently linked to carrier proteins.

Synthetic fibronectin fragments as inhibitors of retroviral infection

The present invention provides a method for treating chronic inflammatory conditions, including autoimmune diseases by administering an effective amount of an agent, such as a nitric oxide synthase inhibitor, a nitric oxide scavenger, or an inhibitor of tetrahydrobiopterin synthesis, to decrease the amount of nitric oxide present at the site of inflammation.

Method of treating chronic inflammatory diseases

Growing community of inventors

Gaithersburg, MD, United States of America

Sharon M Wahl